Cyr61 as mediator of Src signaling in triple negative breast cancer cells by Sánchez-Bailón, María Pilar et al.
Oncotarget13520www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 15
Cyr61 as mediator of Src signaling in triple negative breast 
cancer cells
María Pilar Sánchez-Bailón1,*, Annarica Calcabrini1,2,*, Víctor Mayoral-Varo1,*, 
Agnese Molinari2, Kay-Uwe Wagner3, Jesús Pérez Losada4, Sergio Ciordia5, 
Juan Pablo Albar5,#, Jorge Martín-Pérez1
1 Departamento de Biología del Cáncer, Instituto de Investigaciones Biomédicas A. Sols (CSIC/UAM), Madrid 28029, Spain
2Dipartimento Tecnologie e Salute, Istituto Superiore di Sanità, Roma 00161, Italy
3 Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, 
NE 68198-6805, USA
4Centro de Investigación del Cáncer (CSIC/USAL), Campus Unamuno, Salamanca 37007, Spain
5Servicio de Proteómica, Centro Nacional de Biotecnología (CSIC), Madrid 28049, Spain
*These authors have contributed equally to this work
#This manuscript is dedicated to Juan Pablo Albar who passed away the 19th of July 2014
Correspondence to:
Jorge Martín-Pérez, e-mail: jmartin@iib.uam.es
Keywords: c-Src, Cyr61, triple negative breast cancer, migration, invasion
Received: December 30, 2014  Accepted: April 08, 2015  Published: April 20, 2015
ABSTRACT
SFKs are involved in tumorigenesis and metastasis. Here we analyzed c-Src 
contribution to initial steps of metastasis by tetracycline-dependent expression of a 
specific shRNA-c-Src, which suppressed c-Src mRNA and protein levels in metastatic 
MDA-MB-231 cells. c-Src suppression did not alter cell proliferation or survival, but it 
significantly reduced anchorage-independent growth. Concomitantly with diminished 
tyrosine-phosphorylation/activation of Fak, caveolin-1, paxillin and p130CAS, c-Src 
depletion also inhibited cellular migration, invasion and transendothelial migration. 
Quantitative proteomic analyses of the secretome showed that Cyr61 levels, which 
were detected in the exosomal fraction, were diminished upon shRNA-c-Src expression. 
In contrast, Cyr61 expression was unaltered inside cells. Cyr61 partially colocalized 
with cis-Golgi gp74 marker and with exosomal marker CD63, but c-Src depletion did 
not alter their cellular distribution. In SUM159PT cells, transient c-Src suppression 
also reduced secreted exosomal Cyr61 levels. Furthermore, conditional expression 
of a c-Src dominant negative mutant (SrcDN, c-Src-K295M/Y527F) in MDA-MB-231 
and in SUM159PT diminished secreted Cyr61 as well. Cyr61 transient suppression 
in MDA-MB-231 inhibited invasion and transendothelial migration. Finally, in both 
MDA-MB-231 and SUM159PT, a neutralizing Cyr61 antibody restrained migration. 
Collectively, these results suggest that c-Src regulates secreted proteins, including 
the exosomal Cyr61, which are involved in modulating the metastatic potential of 
triple negative breast cancer cells.
INTRoDUCTIoN
The members of Src family of tyrosine kinases 
(SFKs) are important intracellular mediators of growth 
factors, cytokines, steroid hormones, etc. [1–8]. Also 
integrins stimulate the Fak/Src complex, which in 
turn regulates adhesion, migration, invasion, etc. [9]. 
Consequently, SFKs control signal transduction pathways 
that regulate cell division, motility, adhesion, migration, 
angiogenesis, survival, and differentiation [1, 10–12]. 
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Although there are not consistent evidences for c-Src 
mutations in human tumors [13, 14], deregulation of SFKs 
expression and/or activity is associated with tumorigenesis 
and metastasis [10, 15–17]. Therefore, SFKs are 
therapeutic targets to treat cancer [18].
Numerous evidences support the role of c-Src 
in breast cancer. c-Src is overexpressed and/or hyper-
activated in breast carcinoma tissue of human biopsies 
[19, 20]. Additionally, the relevance of Src in mammary 
tumorigenesis was demonstrated in mice [21]. 
Overexpression and co-association of Her2/Neu and 
c-Src have been described in human breast cancer cell 
lines and tumor samples [15, 22]. Increased expression 
of Src in tumor cells induces phosphorylation and 
inactivation of PTEN, facilitating AKT activation and 
cell survival [23, 24]. Src also promotes proliferation 
by phosphorylation-induced degradation of p27kip1 [25]. 
Similarly, Src phosphorylates estrogen receptor alpha in 
human breast cancer and promotes its proteolysis with 
subsequent therapeutic implications [26].
Src is involved in regulation of migration and 
invasiveness by controlling focal adhesion turnover, 
required for breast cancer metastasis [27–31]. In cancer 
biopsies and metastatic cell lines of human breast, colon 
and rectal cancer, Src tyrosine phosphorylates caveolin-1 
(Y14) increasing tumor cell migration and invasion [32]. 
The catalytic activity of SFKs is necessary for anchorage-
independent growth of metastatic human breast cells 
[30, 33]. Cancer cells secrete soluble molecules and 
microvesicles that contribute to cellular communication 
and cancer dissemination [34]. A comparative 
analysis of exosomal vesicles composition between 
no-metastatic MCF7 and MDA-MB-231 breast cancer 
cells showed, among others, increased levels of matrix 
metalloproteinases in MDA-MB-231 cells that could be 
related to their metastatic nature [35]. Furthermore, Src 
is also involved in angiogenesis and transendothelial 
migration of different tumor cells [36–39].
Breast cancer is a leading cause of death for women 
mainly due to metastasis [40] and SFKs are involved in 
these processes [41–46]. Src kinase activity is required 
for MDA-MB-231 cells to metastasize to bone [47] 
lung [48] and brain [49]. Here we analyzed the role of 
c-Src in metastatic human breast cancer MDA-MB-231 
and SUM159PT cells. Results showed that c-Src is not 
required for MDA-MB-231 cell proliferation or survival, 
but it significantly reduced growth in soft agar. Depletion 
of c-Src significantly inhibited migration, invasiveness, 
and transendothelial migration. Quantitative proteomic 
analyses of the secretome showed that the levels of Cyr61 
(Cysteine-rich protein 61), which was mainly detected 
in the exosomal fraction, were diminished upon c-Src 
knockdown. Similarly, c-Src suppression in SUM159PT 
reduced the amount of Cyr61 in the secretome. Also, 
a dominant negative variant of this kinase (SrcDN, 
c-SrcK295M/Y527F) diminished secreted Cyr61 in 
both cell lines. Furthermore, transient suppression 
of Cyr61 in MDA-MB-231 cells decreased invasion 
and transendothelial migration as well. Consistently, 
neutralizing Cyr61 antibody inhibited MDA-MB-231 and 
SUM159PT cell migration. Together, these results suggest 
that Cyr61 is, at least in part, a c-Src mediator in these 
triple negative breast cancer cell models.
RESULTS
Involvement of c-Src in MDA-MB-231 
proliferation and anchorage-independent growth
To evaluate whether c-Src suppression altered 
proliferation and survival of metastatic MDA-MB-231 
cells, we first generated a derived cell line with conditional 
expression (Tet-On) of a specific shRNA for human 
c-Src, as described in Materials and Methods. Addition 
of Doxy (Doxycycline, 2 μg/ml) to MDA-MB-231-Tet-
On-shRNA-c-Src reduced expression of c-Src mRNA 
and protein in a time-dependent manner (Figure 1A, B). 
To confirm the specificity of the shRNA-c-Src, we 
constitutively expressed chicken c-Src in MDA-MB-
231-Tet-On-shRNA-c-Src cells. We observed that 
depletion of endogenous c-Src upon addition of Doxy 
was compensated by chicken wild type c-Src expression 
(Supplementary Figure 1A).
Interestingly, shRNA-c-Src induction did not 
modify the proliferation of adherent MDA-MB-231-
Tet-On-shRNA-c-Src cells. The results from metabolic 
activity (MTT) and cell viability (Trypan blue) assays 
(Materials and Methods) were similar in control and 
Doxy-treated cells (Figure 1C, D). It should be noted 
that the percentage of Trypan blue-stained cells was 
always smaller than 5% (data not shown), indicating 
that c-Src suppression was not cytotoxic. Furthermore, 
c-Src suppression did not alter expression of cyclin D1 
and p27Kip1 (Figure 1E). Consistently, flow cytometric 
analysis of the cell cycle using propidium iodide labeling 
showed no differences in the percentage of cells in G1, 
S or G2/M phases between untreated and Doxy-treated 
cultures (Figure 1F).
Anchorage-independent growth is a hallmark of 
malignant-cell transformation. Cells were then cultured 
in soft-agar in the absence or presence of Doxy and 
after 20 days, colonies were stained with crystal violet 
and counted. The results shown in Figure 1G revealed 
a significant reduction in the number of colonies bigger 
than 0.1 mm size upon suppression of c-Src. However, 
the analyses of all colonies (bigger than 20 μm) did not 
show differences in the number of colonies after c-Src 
depletion (data not shown). These results suggest that 
c-Src suppression affected colony cell growth.
Oncotarget13522www.impactjournals.com/oncotarget
Figure 1: Involvement of c-Src in cell proliferation and anchorage-independent growth of MDA-MB-231-Tet-on-
shRNA-c-Src. A. To analyze c-Src mRNA and protein expression in MDA-MB-231-Tet-On-shRNA-c-Src cells, total RNA and protein 
were isolated from cells grown with or without Doxy (2 μg/ml) for different times. c-Src mRNA expression was determined by qRT-PCR 
by a TaqMan assay employing TBP as endogenous control (see Materials and Methods). Results are shown as mean ± SD of relative c-Src 
mRNA levels in three independent experiments in triplicate, considering arbitrarily the first sample of Doxy-untreated cells triplicate as 1. 
B. Cell extracts were used to detect c-Src by immunoblotting with MAb-327; membranes were then reblotted with anti-β-actin for 
loading control. Results are representative of three independent experiments. C. Cells were grown with or without Doxy (2 μg/ml) for 
72 h. Metabolic activity was determined by MTT assay measuring absorbance at 570nm. Results are expressed as mean ± SD from three 
independent experiments in triplicate. D. Cell viability was evaluated counting cells after Trypan blue labeling. Results are shown as 
mean ± SD from four independent experiments in triplicate. E. Extracts from control and Doxy-treated cells were blotted with Cyclin D1 
and p27Kip1 antibodies. Membranes were reblotted with anti-α-tubulin for loading control. Results are representative of three independent 
experiments. F. Cells were collected fixed with 70% ethanol in PBS at 4°C, washed with PBS and incubated with RNAase and propidium 
iodide for 1 h at 37°C, cell acquisition was performed with FACScan flow cytometer (BD). Percentages of cell cycle phases (G1, S, G2/M) 
were calculated from DNA histograms by CellQuest software. Results are shown as mean ± SD from four independent experiments. 
G. Number of colonies/plate obtained after cell growth in soft-agar (20 days -/+ 2 μg/ml Doxy) (see Material and Methods). Colonies 
were stained with crystal violet and counted by phase contrast microscopy. Average ± SD from three independent experiments in triplicate 
(*p < 0.05).
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Suppression of c-Src reduced cell migration, 
transendothelial migration and invasiveness
We have previously shown that inhibition of 
Src family tyrosine kinase activity in MDA-MB-231 
reduced cell migration [31]. We tested here whether 
c-Src suppression could modify migration properties. 
Cells were grown to confluence for 48 h in absence or 
presence of Doxy (2 μg/ml); after scratching and renewing 
media -/+ Doxy, cultures were placed in a Microscope Cell 
Observer and pictures were taken at 0 and 20 h. Analyses 
of images with the wound-healing tool of ImageJ showed 
that addition of Doxy to the cultures caused a significant 
reduction of cell migration (Figure 2A). Furthermore, 
random migration analysis of sub-confluent cultures 
showed a significant reduction of the mean velocity and 
distance travelled by Doxy-treated cells as compared to 
control (Supplementary Figure 2A, B).
Association of Src with Fak controls turnover 
of focal adhesion complexes, which are involved in 
cell motility. Therefore, we analyzed the effect of 
c-Src suppression on the degree of phosphorylation/
activation of Fak, caveolin-1, paxillin and p130CAS. 
Total cell extracts from exponentially growing cultures 
in absence or presence of Doxy for 72 h were analyzed 
by immunoblotting. Results showed that shRNA-c-Src 
induction reduced phosphorylation of Fak at Y397, the 
autophosphorylation site, and at Y925, which is a substrate 
for Src tyrosine kinase activity [50]. It also diminished 
the phosphorylation of caveolin-1 at Y14, paxillin at Y118 
and tyrosine phosphorylation of p130CAS (Figure 2B). 
These results are consistent with the observed decrease 
in cell migration. The constitutive expression of wild-
type chicken c-Src in c-Src depleted cells restored their 
migration ability. Furthermore, the activation of Fak, 
caveolin, and paxillin was no longer reduced upon c-Src 
suppression (Supplementary Figure 1B), confirming the 
specificity of the shRNA-c-Src employed in our model.
Extravasation and intravasation are events 
required for tumor-cell metastasis. To test whether c-Src 
could influence transmigration through endothelium, 
we performed transendothelial migration assays. 
Exponentially growing cultures in absence or presence 
of Doxy for 48 h were seeded on a HUVEC monolayer 
in cell culture inserts. In parallel, to determine HUVEC 
spontaneous migration a control was performed in the 
same conditions by seeding endothelial cells alone. After 
22 h, the analysis of transmigrated cells showed that 
shRNA-c-Src induction by Doxy significantly reduced 
transendothelial migration (Figure 2C).
Numerous studies support the role of Src kinases 
in cellular invasion [10]. Since MDA-MB-231 cells are 
highly metastatic [47], we determined the effect of c-Src 
suppression in the invasive properties of this cellular 
model. Control and Doxy-treated cultures (48 h) were 
seeded onto Matrigel-coated cell culture inserts and 
allowed to invade for 22 h in the presence or absence of 
Doxy (see Materials and Methods). The results revealed 
that c-Src suppression significantly inhibited cellular 
invasive ability (Figure 2D). In addition, ablation of this 
kinase reduced the levels of matrix metalloproteinases 
MMP2, MMP7 and MMP9 in the secretome (Figure 2E). 
Similar results were obtained in MDA-MB-231-Tet-On-
SrcDN that conditionally expresses a dominant negative 
form of c-Src (SrcDN: c-Src-K295M/Y527F), which 
is devoid of catalytic activity but with functional SH2 
and SH3 domains. Addition of Doxy did not alter cell 
proliferation but reduced cellular migration and invasion 
(Supplementary Figure 3A–C). Accordingly, reduced 
levels of MMP2, MMP7, and MMP9 were identified in 
the secretome of these cells (Supplementary Figure 3E).
Proteomic analyses of the secretome
Since c-Src appears to be important for cellular 
invasiveness, we analyzed whether its ablation 
modified other secreted proteins in addition to matrix 
metalloproteinases. Conditioned media were collected 
from cells grown in absence or presence of Doxy for 
72 h. Proteins contained in total secretome (fraction S3, 
see diagram of Figure 4A) were submitted to quantitative 
proteomic analyses (HPLC- MS/MS) after labeling 
tryptic-peptides with iTRAQ. Peptides were then identified 
employing the two different search engines Mascot 
and Phenyx (Materials and Methods). The data showed 
that c-Src suppression diminished the levels of 13 and 
increased the levels of 7 proteins in secretome (Table 1).
The protein showing the highest reduction upon 
c-Src ablation, about 3.5 fold, was Cyr61 (Cysteine-
rich protein 61, CCN1), an extracellular matrix-
associated protein involved in migration and invasion of 
MDA-MB-231 cells [51]. Analyses of total secretome by 
immunoblotting confirmed reduced expression of Cyr61 
in Doxy-treated cells (Figure 3A). To verify whether 
Doxy-treatment of wild-type MDA-MB-231 cells altered 
Cyr61 levels, we analyzed Cyr61 in the secretome, but no 
alterations were detected (data not shown). When chicken 
c-Src was constitutively expressed in c-Src suppressed 
MDA-MB-231 cells, the secreted Cyr61 levels were 
restored, confirming once again the specificity of the 
shRNA-c-Src (Supplementary Figure 1C).
Next, we evaluated whether c-Src suppression 
changed the intracellular levels of CCN1/Cyr61 
mRNA and protein. Total RNA was isolated from 
exponentially growing cultures in presence or absence of 
Doxy (2 μg/ml for 72 h), and levels of mRNA and protein 
were determined by qRT-PCR and immunoblotting (see 
Materials and Methods). Surprisingly, suppression of 
c-Src did not seem to alter the intracellular content of 
mRNA and protein of CCN1/Cyr61 (Figure 3B). To 
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Figure 2: Role of c-Src in migration and invasion properties of MDA-MB-231-Tet-on-shRNA-c-Src cells. A. Cell 
migration was determined by wound-healing assay through scratching confluent cultures; photomicrographs were taken at 0 and 20 h with 
a Microscope Cell Observer Z1 system, and quantified using wound-healing tool of ImageJ. Results are expressed as mean percentage of 
wound healing area ± SD at 20 h respect to 0 h from three independent experiments (**p < 0.01). B. Expression of phosphoproteins/proteins 
involved in cell motility by immunoblotting. Extracts from control and treated cells (2 μg/ml Doxy, 72 h) were blotted with antibodies to 
c-Src (MAb-327), pY397-Fak, pY925-Fak, pY14-Caveolin and pY118-Paxillin. p130CAS was immunoprecipitated from total cell extracts 
and immune-complexes blotted with anti-pY (4G10). Membranes were reblotted with anti-β-actin (for c-Src) and anti-total-protein (for 
phosphoproteins) for loading control. Results are representative of three independent experiments. C. Transendothelial migration through 
a HUVEC monolayer. Cells were grown for 48 h -/+ 2 μg/ml Doxy and then seeded on the HUVEC monolayer. Transmigrated cells were 
detached after 22 h and counted in a hemocytometer. The number of Doxy-treated transmigrated cells was expressed as percentage of 
control transmigrated cells (100%). Assay was repeated three times (*p < 0.05). D. For cell invasion through Matrigel-coated inserts, 
cultures were grown for 48 h -/+ 2 μg/ml Doxy and then seeded onto Matrigel (-/+ 2 μg/ml Doxy); 22 h later, cells on the top of inserts were 
removed and invaded cells were fixed, stained with DAPI and counted by fluorescence microcopy. The number of invaded cells per insert 
is shown and represents average ± SD of four experiments in triplicate (**p < 0.01). E. Analysis of secreted metalloproteinases MMP2, 
MMP7 and MMP9 from equal number of control or Doxy-treated cells (2 μg/ml) for 72 h. Conditioned media were used to prepare total 
soluble fraction of secretome by differential centrifugation (S3, Figure 4A). After concentration by methanol/chloroform precipitation, 
pellet was resuspended in RIPA for immunoblotting analyses (see Material and Methods). Results are representative of three independent 
experiments.
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Table 1: Quantitative proteomic analysis of secretome from MDA-MB-231-Tet-on-shRNA-c-Src 
cells
PRoTEIN AC Description
Mascot AverageRatio Ctrl/Doxy Phenyx AverageRatio Ctrl/Doxy
iTRAQ1 iTRAQ2 iTRAQ1 iTRAQ2
O00622
Protein CYR61 OS 
= Homo sapiens GN 
= CYR61 PE = 1 SV = 1
3.569 4.423 3.512 3.470
P61769
Beta-2-microglobulin OS 
= Homo sapiens GN = 
B2M PE = 1 SV = 1
1.608 1.568 1.575 1.368
P22692
Insulin-like growth 
factor-binding protein 4 
OS = Homo sapiens GN 
= IGFBP4 PE = 1 SV = 2
1.546 1.415 1.408 1.292
P29279
Connective tissue growth 
factor OS = Homo 
sapiens GN = CTGF PE 
= 1 SV = 2
1.519 1.414 1.541 1.370
P01034
Cystatin-C OS = Homo 
sapiens GN = CST3 PE 
= 1 SV = 1
1.441 1.352 1.402 -
P16035
Metalloproteinase 
inhibitor 2 OS = Homo 
sapiens GN = TIMP2 PE 
= 1 SV = 2
1.440 1.459 1.426 1.438
P07996
Thrombospondin-1 OS 
= Homo sapiens GN 
= THBS1 PE = 1 SV = 2
1.433 1.454 1.337 1.303
P80188
Neutrophil gelatinase-
associated lipocalin OS 
= Homo sapiens GN 
= LCN2 PE = 1 SV = 2
1.431 1.492 1.487 1.523
Q16270
Insulin-like growth 
factor-binding protein 7 
OS = Homo sapiens GN 
= IGFBP7 PE = 1 SV = 1
1.425 1.434 1.381 1.376
Q14697
Neutral alpha-glucosidase 
AB OS = Homo sapiens 
GN = GANAB PE = 1 
SV = 3
1.414 - 1.279 -
P04004
VTNC_HUMAN 
Vitronectin OS = Homo 
sapiens GN = VTN PE 
= 1 SV = 1
- - 1.235 1.613
(Continued )
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support these observations, we analyzed the effects of 
c-Src suppression in another triple negative breast cancer 
cell line, SUM159PT. When c-Src was suppressed by 
means of a specific siRNA in SUM159PT (Figure 3C), 
the amount of Cyr61 was highly reduced in the secretome, 
as well as intracellularly (Figure 3C, D), in contrast to the 
results obtained in MDA-MB-231 cells.
Similarly to c-Src knockdown, conditional 
expression of SrcDN in MDA-MB-231 cells did not 
modify CCN1/Cyr61 mRNA and protein levels in cells 
(Supplementary Figure 3D), but it diminished the levels 
of Cyr61 in the secretome (Supplementary Figure 3E). 
Analogous results were obtained for SUM159PT after 
conditional expression of SrcDN (Supplementary 
Figure 3F).
To further characterize the mechanisms by which 
c-Src may influence Cyr61 secretion, we determined 
whether Cyr61 was a soluble protein or associated with 
the vesicular fraction of the secretome. Since suppression 
of c-Src in MDA-MB-231 cells did not alter cell 
proliferation or viability (Figure 1), conditioned media 
from equal numbers of untreated or Doxy-treated cells 
were fractionated using differential centrifugation [52]. 
Proteins from supernatants 3, 4 and 5 (S3, S4 and S5, 
PRoTEIN AC Description
Mascot AverageRatio Ctrl/Doxy Phenyx AverageRatio Ctrl/Doxy
iTRAQ1 iTRAQ2 iTRAQ1 iTRAQ2
O00300
TR11B_HUMAN Tumor 
necrosis factor receptor 
superfamily member 11B 
OS = Homo sapiens GN 
= TNFRSF 11B PE = 1 
SV = 3
- 1.342 - 1.409
P07858
Cathepsin B OS = Homo 
sapiens GN = CTSB PE 
= 1 SV = 3
1.214 1.420 1.214 1.313
P04179
Superoxide dismutase 
[Mn], mitochondrial OS 
= Homo sapiens GN 
= SOD2 PE = 1 SV = 2
0.789 0.707 0.789 0.708
Q5QNW6
Histone H2B type 2-F 
OS = Homo sapiens GN 
= HIST2H2BF PE = 1 
SV = 3
0.739 0.668 0.588 0.706
P29401
Transketolase OS 
= Homo sapiens GN 
= TKT PE = 1 SV = 3
0.707 0.678 0.767 0.848
P02768
Serum albumin OS 
= Homo sapiens GN 
= ALB PE = 1 SV = 2
0.580 0.630 0.624 0.655
P62805
Histone H4 OS = Homo 
sapiens GN = HIST1H4A 
PE = 1 SV = 2
0.569 0.609 0.567 0.647
Q71DI3
Histone H3.2 OS = Homo 
sapiens GN = HIST2H3A 
PE = 1 SV = 3
0.543 0.528 0.558 0.594
P0C0S8
Histone H2A type 1 OS 
= Homo sapiens GN 
= HIST1H2AG PE = 1 
SV = 2
0.443 0.513 0.461 0.513
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see diagram of Figure 4A) were subsequently concentrated 
by methanol/chloroform precipitation, and together with 
pellet 5 (P5) analyzed by immunoblot to detect Cyr61. 
Results showed that Cyr61 was mainly found in P5. In 
addition, the exosomal marker tetraspanin CD63 [53] 
was exclusively detected in this fraction that contains 
exosomes [52]. Cyr61 was also weakly detected in 
soluble secretome of the S4 of control cells that were not 
treated with Doxy. Furthermore, statistical analyses of 
immunoblot-signals from four independent experiments 
showed that treatment with Doxy significantly reduced 
only expression of Cyr61 (Figure 4A).
To clarify the role of c-Src on exosomal protein 
secretion, the number of secreted vesicles was quantified 
in the exosomal fraction (P5) obtained from culture media 
of control and c-Src depleted MDA-MB-231 cells (see 
Supplementary Materials and Methods). Suppression 
of c-Src did not modify the number of total exocytic 
vesicles and of exosomes (size between 50 and 150 nm) 
(Supplementary Figure 4A and B, respectively), suggesting 
that c-Src does not modulate their secretion. Furthermore, 
the total protein concentration of fractions S3 and P5 
were unaltered upon c-Src suppression (Supplementary 
Figure 4C). Moreover, siRNA suppression of Rab27a, 
which controls the exosomal secretion pathway [54], 
significantly reduced the expression of both Cyr61 and 
CD63 in the secretome (Figure 4B). However, it did not 
statistically alter their intracellular levels (Figure 4C). It is 
important to indicate that c-Src suppression did not modify 
cellular expression of Rab27a (Supplementary Figure 5). 
Furthermore, we observed that Cyr61 was mainly found 
in exosomes not only in MDA-MB-231, but also in 
SUM159PT, as transient expression of siRNA-c-Src 
in SUM159PT also showed a reduction of Cyr61 levels 
in exosomes (fraction P5), while CD63 levels remained 
unaltered (Supplementary Figure 6).
Additionally, we evaluated co-localization of Cyr61 
with markers of secretory pathways, such as the cis-Golgi 
marker gp74 [55], and the late endosomal, lysosomal, 
and exosomal marker CD63 [53] in MDA-MB-231 
Figure 3: c-Src suppression reduces Cyr61 in MDA-MB-231-Tet-on-shRNA-c-Src and in SUM159PT cells. A. Conditioned 
media from equal number of control or Doxy-treated MDA-MB-231-Tet-On-shRNA-c-Src were used to prepare secretome (S3 fraction) 
by centrifugation as in Figure 4A. After concentration by methanol/chloroform precipitation, pellet was used for detection of Cyr61 by 
immunoblotting. Quantitation of 4 independent experiments by ImageJ is shown. B. Analysis of Cyr61 mRNA and protein in total cell 
extracts from control and Doxy-treated (2 μg/ml) cultures grown for 72 h. Cyr61 (CCN1) mRNA expression was determined by qRT-PCR 
employing GAPDH as endogenous control (see Materials and Methods). Results are shown as mean ± SD of relative Cyr61 mRNA levels 
in three independent experiments in triplicate, considering arbitrarily the first sample of Doxy-untreated cells triplicate as 1. Intracellular 
Cyr61 was analyzed by immunoblotting, and α-tubulin was used for loading control. Quantitation of 3 independent experiments by ImageJ 
is shown. (**p < 0.01). C. c-Src was suppressed in SUM159PT cells by transient transfection of siRNA-hs-c-Src (see Materials and 
Methods), and levels of c-Src and Cyr61 were determined by immunoblotting in total cell extracts. D. Detection of Cyr61 levels in the 
secretome derived from equal number of SUM159PT cells after c-Src depletion.
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cells. Analyses of confocal microscopy images showed a 
partial co-localization of Cyr61 with both gp74 and CD63 
(Pearson’s coefficient: 0.60 and 0.54, respectively) [56], 
as well as in Doxy-treated cells (Pearson’s coefficient: 
0.64 and 0.51, respectively) but no differences were 
observed between untreated and Doxy-treated cells 
Figure 4: Analyses of cellular and secretome Cyr61distribution. A. Fractionation of secretome by differential centrifugation 
from MDA-MB-231-Tet-On-shRNA-c-Src cultures grown in presence or absence of Doxy (2 μg/ml) for 72 h. After protein concentration 
by methanol/chloroform precipitation of fractions, expression of Cyr61 and CD63 was analyzed by immunoblotting. ImageJ densitometry 
quantification of four independent experiments (mean ± SD) is reported below and expressed in arbitrary units (**p < 0.01). B., C. MDA-
MB-231 cells were transiently transfected with either scramble siRNA (Ctrl) or Rab27a-SiRNA (Rab27a) for 96 h. In secretome fraction S3, 
obtained from cultures with equal number of cells, and expression of Cyr61 and CD63 determined by immunoblotting B. Expression 
of Cyr61, CD63 and Rab27a was determined by immunoblotting in total cell extracts. Membranes were reblotted with anti-β-actin for 
loading control C. ImageJ densitometry quantification of three independent experiments (mean ± SD) is reported below and expressed as 
Target/β-actin ratio (for total cell extract) or in arbitrary units (for secretome) (*p < 0.05, ***p < 0.001).
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(Supplementary Figure 7A, B). Together, these results 
suggest that c-Src controls levels of exosomal Cyr61.
Silencing Cyr61 reduced invasion and 
transendothelial migration
The above data indicate that c-Src suppression 
reduced invasiveness and transendothelial migration, 
which are properties of metastatic cells, and also 
diminished the levels of Cyr61 in the secretome. To 
elucidate whether Cyr61 mediated c-Src biological 
effects in MDA-MB-231 cells, we investigated the 
cellular invasiveness and transendothelial migration of 
cells following the siRNA-mediated depletion of Cyr61. 
Exponentially growing MDA-MB-231 cultures were 
transiently transfected with scramble-siRNA (Ctrl) and 
Cyr61-siRNA as described in Materials and Methods. 
Compared to control siRNA, specific Cyr61 siRNA 
significantly reduced Cyr61 expression (Figure 5A), 
as well as invasion and transendothelial migration 
(Figure 5B, C).
Neutralization of Cyr61 reduced cell migration
Furthermore, to determine if secreted Cyr61 had a 
role in cell migration, cultures of MDA-MB-231-Tet-On-
shRNA-c-Src or SUM159PT were incubated with either 
Cyr61 antibody (α-Cyr61) or with the corresponding 
amount of normal rabbit serum (Ctrl) in wound-healing 
assays. Antibody neutralization of Cyr61 significantly 
reduced cell migration as compared with the control 
(normal rabbit serum) both in MDA-MB-231-Tet-On-
shRNA-c-Src and SUM159PT cell lines (Figure 5D, E, 
respectively).
These results support the role of Cyr61 as a mediator 
of c-Src signaling in the regulation of these cellular events, 
which are associated with metastatic properties of triple 
negative breast cancer cells.
Figure 5: Effect of Cyr61 suppression or antibody neutralization on breast cancer cell motility properties. A. MDA-
MB-231 were transiently transfected with siRNA-Cyr61 for 72 h and, Cyr61 expression determined from total cell extracts by immunoblotting. 
Membranes were reblotted with anti-α-tubulin for loading control. Results are representative of three independent experiments in triplicate. 
B. For cell invasion through Matrigel-coated inserts, 48 h after siRNA-Cyr61 or siRNA-Control transfected cells were loaded onto Matrigel. 
After 22 h, invaded cells were fixed, stained with DAPI and counted by fluorescence microcopy. The number of invaded cells per insert is 
shown and represents average ± SD of three experiments performed in triplicate (**p < 0.01). C. For transendothelial migration, cells were 
seeded onto the HUVEC monolayer, and 48 h after siRNA-Cyr61 transfection. Transmigrated cells were detached after 22 h and counted 
in a hemocytometer. The number of siRNA-Cyr61 transmigrated cells was expressed as percentage of siRNA-Control transmigrated cells 
(100%). D. Cultures of MDA-MB-231-Tet-On-shRNA-c-Src in absence of Doxy were treated with 4 μg/ml of anti-Cyr61 (Cyr61) or with 
the corresponding amount of normal rabbit serum (Ctrl) for 48 h. E. Cultures of SUM159PT were treated with 1 μg/ml of anti-Cyr61 or 
with the corresponding amount of normal rabbit serum (Ctrl) for the last 20 h. Analyses of wound-healing were made at 0 and 20 h as 
described in Materials and Methods. Results are expressed as mean percentage of wound healing area ± SD at 20 h respect to 0 h from three 
independent experiments performed in triplicate (*p < 0.05, **p < 0.01).
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Expression of Cyr61 in breast cancer
Cyr61 has been involved in breast cancer [51, 57], its 
expression correlates with lack of estrogen receptor [58]. 
To determine whether there is a relationship between 
Cyr61 expression and the different breast cancer subtypes 
(Luminal A and B, Basal A and Basal B), we analyzed its 
levels in 51 human breast cancer cell lines according to 
published data [59]. The results showed that the lowest 
levels of Cyr61 were found in Luminal A and B subtypes 
(Figure 6A). Furthermore, it was differentially expressed 
in ER- breast cancer subtypes, since Cyr61 mRNA levels 
was higher in Basal B than in Basal A subtype. Basal 
B cell lines, like MDA-MB-231 or SUM159PT have a 
mesenchymal-like phenotype and features of cancer stem 
cells (CD44+ CD24-/low, ALDH1+) [60], indicating that 
Cyr61 is associated with a more aggressive phenotype. In 
fact, analyses of 581 human samples of Basal-like tumors 
[St Gallen International Expert Consensus on the Primary 
Therapy of Early Breast Cancer 2011 [61]] by Kaplan-
Meier plotter based on RFS (Relapse Free Survival) [62], 
showed that high expression of Cyr61 was significantly 
associated to lower probability of RFS (Figure 6B).
DISCUSSIoN
SFKs participate in the development and 
progression of several human cancers, including breast 
cancer. Furthermore, SFKs are involved in MDA-
MB-231 metastasis to bone, lung [47, 48] and brain [49]. 
To investigate the role of c-Src in the first steps that lead 
to metastasis, we generated three inducible cell lines, 
MDA-MB-231-Tet-On-shRNA-c-Src, MDA-MB-231-Tet-
On-SrcDN, and SUM159PT-Tet-On-SrcDN. In addition, 
c-Src was transiently suppressed in SUM159PT cells. 
We found that c-Src modulates migration, invasion and 
transendothelial migration processes by regulating the 
phosphorylation of focal adhesion proteins along with 
the levels of secreted proteins such us IGFBP4, CTGF, 
and Cyr61, a new exosomal protein involved in tumor 
progression.
An essential property of metastatic cells is their 
capacity to grow in the absence of a substrate. Our 
findings show that c-Src suppression significantly reduced 
the capacity of MDA-MB-231 cells to grow as colonies 
in soft agar. Previous results support the role of c-Src in 
anchorage-independent growth. Silencing of c-Src, but 
not Yes or Fyn, reduced the ability to form colonies in 
MDA-MB-231, MDA-MB-436 and SKBR3 cells [63]. 
Furthermore, SFKs catalytic activity inhibition or stable 
transfection of catalytically inactive c-Src into MDA-
MB-468 and MCF7 reduced colony formation ability [33]. 
Therefore, c-Src is required for breast cancer cell growth 
in anchorage-independent conditions.
SFKs participate in focal adhesion turnover that 
control cell motility and, in turn, cell migration and 
invasion. Fak/Src complex phosphorylates several proteins 
including p130CAS, paxillin or caveolin 1 promoting focal 
adhesion turnover [64, 65]. c-Src suppression decreased 
cell migration and invasion, as well as diminished 
Figure 6: Expression of Cyr61 in breast cancer. A. Different expression levels of Cyr61 in human cell lines of breast cancer of 
Luminal A (ER +), Luminal B (ER-), Basal A, and Basal B (i.e. with epithelial to mesenchymal transition). Notice that the last group shows 
the higher levels of Cyr61 expression. Below, Cyr61 is significantly expressed at higher levels in cell lines that had undergone epithelial to 
mesenchymal transition. Figure generated from the available database [59]. Comparison among groups was done by ANOVA followed by 
Tukey post-hoc test. B. Levels of Cyr61 expression define tumor prognosis of patients with breast cancer of basal origin. Figure generated 
with the Kaplan-Meier plotter available at the web page: http://kmplot.com/analysis/index.php?p=service from the database [62].
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phosphorylation of Y-p130CAS, Y118-paxillin, and 
Y14-caveolin 1. Additionally, SrcDN expression also 
reduced cell migration and invasion. SFKs catalytic 
activity inhibition provoked comparable effects on MDA-
MB-231 cells [31]. Analogous results were obtained 
after SrcDN constitutive expression in MDA-MB-231 
cells [41]. In MCF7 cells constitutive suppression of c-Src 
or SrcDN conditional expression reduced cell migration 
[36]. Matrix metalloproteases degrade extracellular 
matrix proteins and, therefore, are necessary for cell 
invasion [66]. We also observed that c-Src depletion or 
SrcDN expression in MDA-MB-231 reduced the levels of 
the matrix metalloproteases MMP2, MMP7, and MMP9 
in the secretome. Previous observations show that SFKs 
catalytic activity inhibition by PP2 in MDA-MB-231 
cells decreased MMP9 production, as well as invadopodia 
formation [67]. Besides, PH006, another SFKs catalytic 
activity inhibitor, reduced MMP2 and MMP9 secretion 
and invasion of MDA-MB-231 cells [68]. These findings 
suggest that c-Src is essential for cell migration and 
invasion.
To further characterize the contribution of c-Src in 
both events we analyzed the secretome of c-Src-depleted 
MDA-MB-231 cells. Twenty proteins were differentially 
expressed, 13 were down-regulated and 7 up-regulated. 
Among the down-regulated proteins, we found Cysteine-
rich protein 61 (Cyr61), Insulin-like growth factor-
binding protein 4 (IGBP4), and Connective tissue growth 
factor (CTGF). However, MMPs were undetected in the 
proteomic analyses because the immunoblotting was more 
sensitive under the experimental design employed (see 
Materials and Methods). The most differentially down-
regulated protein was Cyr61, a CCN family member that 
participates in cell migration, differentiation, proliferation, 
adhesion, and angiogenesis [69]. The reduction in secreted 
Cyr61 did not correspond to the unaltered intracellular 
mRNA and protein levels observed in c-Src-depleted 
MDA-MB-231 cells. Furthermore, this is not an off-
target effect of the shRNA-c-Src, since the constitutive 
expression of chicken c-Src restored Cyr61 levels in the 
secretome.
It is known that Cyr61 is highly expressed in 
invasive breast cancer cell lines, and its expression 
correlates with the absence of estrogen receptor [58]. We 
observed the lowest levels in Luminal A and B subtypes 
and the highest in Basal cells. Moreover, the most 
aggressive basal-like subtype, Basal B, has significantly 
higher levels of Cyr61 than Basal A. Cyr61 was expressed 
in 36% of primary breast tumors [70] and in about 30% of 
invasive breast carcinomas. High Cyr61 levels are related 
to advance stage and tumor size [71, 72]. We found that 
higher Cyr61 expression significantly reduced probability 
of relapse free survival, by the analyses of 581 human 
samples of basal-like tumors. Therefore, Cyr61 could be a 
marker of poor prognosis in basal breast carcinoma.
In MDA-MB-231 cells constitutive expression 
of Sonic Hh (SHH) increased secreted Cyr61. Besides, 
silencing of Cyr61 reduced invasion of SHH-expressing 
MDA-MB-231 cells, as well as diminished the ability to 
induce endothelial tube. Moreover, Cyr61 knockdown 
reduced tumor growth [73]. The ectopic expression of 
Cyr61 in MCF7 promoted estrogen-independent growth, 
and its overexpression increases tumors growth, as well as, 
density of blood vessel in tumors [70, 74]. We observed 
diminished invasive and transendothelial migration 
abilities after c-Src suppression, as well as, after transient 
silencing of Cyr61 in MDA-MB-231 cells. Moreover, 
neutralization of secreted Cyr61 reduced cell migration 
in MDA-MB-231 and SUM159PT cells. Similarly, Cyr61 
neutralization reduced MDA-MB-231 migration and 
invasion in vivo and in vitro [51]. Together, these data 
support the role of Cyr61 as a mediator, at least in part, for 
the role of c-Src in invasion and extravasation.
Cyr61 is associated with the extracellular matrix 
and we found a small portion in soluble secretome. 
However, Cyr61 was mainly present in the exosomal 
fraction. Knockdown of Rab27a, a small GTPase involved 
in exosomal secretion [54], resulted in reduced levels of 
CD63 and Cyr61 in the secretome. We observed a partial 
co-localization of Cyr61 with markers of the secretory 
pathway, including the cis-Golgi marker gp74 [55], as 
well as, CD63, a marker of late endosomes, lysosomes and 
exosomes [75, 76]. However, we could not discriminate 
the effects of c-Src on this part of the secretory pathway. 
Furthermore, the reduced levels of Cyr61, MMP2, MMP7 
and MMP9 in the secretome upon c-Src suppression in 
MDA-MB-231 cells is not a general effect of this proto-
oncogene on protein secretion, as the total number of 
exocytic vesicles and exosomes was not modified, nor 
was the protein concentration of fraction S3 and P5. In 
view of the results, we could hypothesize that the absence 
of c-Src might favor Cyr61 proteolysis in the secretome 
by protease activation. c-Src suppression reduced 
intracellular Cyr61 in SUM159PT, concomitantly with an 
increase in the cysteine protease cathepsin F, not observed 
in MDA-MB-231 (data not shown). Moreover, Src family 
kinase activity inhibition by Dasatinib or PP2 in MDA-
MB-231 also diminished intracellular Cyr61 levels (data 
not shown), while cathepsin F mRNA was increased [31]. 
Indeed, we observed that the levels of cystatin C, an 
inhibitor of cysteine proteases, were reduced in the 
secretome of c-Src-depleted MDA-MB-231 cells. Then, 
further studies are required to determine the molecular 
mechanisms by which c-Src controls secreted Cyr61.
Exosomes transfer information and act locally on 
cancer cells and stroma, or distantly to prepare niche for 
cancer cell implantation. Melanoma-derived exosomes 
promote metastatic niche formation through modification 
of bone marrow-derived cells. Exosomes from a metastatic 
melanoma cell line injected in mice localized to common 
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sites of melanoma metastasis such as, lung, bone 
marrow, liver, and spleen [77]. Cyr61 is involved in bone 
remodeling, acting on osteoblast differentiation [78, 79] 
and its silencing in osteosarcoma tumors reduced 
vascularization and metastases to lung [80]. Then, we 
cannot discard its contribution to lung and bone metastasis 
of breast cancer cells. Furthermore, an up-regulation of 
Cyr61 and CTGF was observed in bone-derived MDA-
MB-231 cells compared to parental MDA-MB-231 
cells [81]. CTGF, another CCN member, participates in 
osteolytic metastasis of highly aggressive bone-derived 
MDA-MB-231 population [82]. Moreover, CTGF-
integrin αvβ3-Erk1/2 pathway regulates S100A4 gene that 
contributes to metastatic ability of MDA-MB-231 cells 
in a lung metastatic mouse model [83]. Therefore, c-Src 
might alter metastatic potential of triple negative breast 
cancer cells by modulating secreted proteins including 
Cyr61 and CTGF.
In conclusion c-Src modulation may be essential to 
breast cancer metastasis, since regulates MDA-MB-231 
cell survival in absence of substrate. Besides, c-Src 
modulates invasion, migration, and transendothelial 
migration, essential processes in metastatic cascade, 
by controlling secreted proteins, particularly the new 
exosomal protein, Cyr61.
MATERIALS AND METhoDS
Reagents
Anti-c-Src MAb-327 [84], provided by J.S. Brugge, 
Harvard University. Anti-Fak, anti-Cyr61, and anti-cyclin 
D1 were from Santa Cruz Biotechnology. Anti-CD63 
(Inmuno-Step; Calbiochem). Antibodies to MMP2, 
MMP9, and MAb 4G10 were from Merk-Millipore. Anti-
MMP7 was from Abgent. Anti-pY397-Fak, secondary 
horseradish peroxidase-conjugated antibodies, siRNA-
hs-Cyr61 (s7244, Silencer® selected and validated 
siRNA), siRNA-hs-c-Src (s13414, Silencer® selected and 
validated siRNA), and scramble siRNA (Stealth RNAi 
Negative Control Duplex #12935–300) were from Life 
Technologies. Anti-pY925-Fak was from Cell Signaling 
Technologies. Anti-paxillin, anti-pY118-paxillin, anti-
p130CAS, anti-caveolin-1, anti-pY14-caveolin-1, 
anti-p27Kip1, and MatrigelTM were from BD-Biosciences. 
Anti-α-tubulin, anti-ß-actin, doxycycline (Doxy), Trypan 
blue, Thiazolyl Blue Tetrazolium Bromide (MTT reagent), 
and esiRNA human Rab27a were from Sigma-Aldrich. 
Anti-Rab27a polyclonal antibody (Peter van der Sluijs, 
University Utrecht, [85]). Anti-Tet-repressor (Mobitec). 
Blasticidin and zeocin were from InvivoGen. Tet-Free-
FCS (PAA Laboratories GmbH). Acrylamide/Bis-
acrylamide (29:1), SDS and ammonium persulfate were 
from Bio-Rad Laboratories. ECL was from GE Healthcare 
Biosciences. BCA protein assay and DharmaFECT 4 
were from Thermo Scientific.
Generation of MDA-MB-231 cell line with 
conditional expression (Tet-on) of shRNA-c-Src
Genotyped MDA-MB-231 (ATCC, HTB-26) 
cultured in DMEM containing 5% Tet-free FCS, 
2mM glutamine, 100IU/ml penicillin, and 100 μg/ml 
streptomycin were transfected with pcDNA6/TR (Life 
Technologies) and selected with 6 μg/ml of blasticidin. 
Clones were grown and tested for maximal expression 
of TetR by immunoblotting. Clone TR8 was transfected 
with pENTR™/H1/TO containing the highly specific 
shRNA-c-Src: 5’-GCCTCAACGTGAAGCACTACA-3’ 
(100% identity and E-value 0.006 for mRNA transcripts 
variants 1 and 2, NM-198291 and NM-005417.4, of 
human c-Src by BLAST analysis) (Life-Technologies). 
After 48 h, cells were selected with blasticidin and 
300 μg/ml of zeocin. Clones were grown -/+2 μg/ml 
Doxy for 72 h, and tested for c-Src expression by 
immunoblotting. Clones with high reduction of c-Src 
expression were pooled. Then, total RNA and protein 
were isolated from cells grown -/+ Doxy for different 
times and tested for c-Src mRNA by qRT-PCR and 
protein expression by immunoblotting.
Transient transfection of siRNA-c-Src in 
SUM159PT
The triple negative human breast cancer cells 
SUM159PT [86], provided by G. Dontu [87], were 
propagated in Ham’s F12, 5% FCS, 5 μg/ml insulin, 
1 μg/ml hydrocortisone, 2mM glutamine, 100IU/ml 
penicillin, and 100 μg/ml streptomycin. For transient 
transfection, SUM159PT cells (1.5x105cells/well, 
6-well plate) were seeded in complete medium without 
antibiotics. Next day, cells were transfected with 20nM 
of siRNA-hs-c-Src or 20nM scramble siRNA for control, 
using Dharmafect 4. After 8 h medium was changed, 
and cells were cultured for 48 h, then the media was 
replaced for serum-free media, and cultures maintained 
for another 24 h. Secretome and total cell extracts were 
used for immunoblotting analyses.
Metabolic activity and cell viability studies
For MTT assay, cells were incubated in the presence 
or absence of Doxy (2 μg/ml) for 72 h. Then, 10 μl of 
MTT reagent were added to each well (final concentration 
0.5mg/ml) and plates were incubated at 37°C for 4 h. 
After solubilization of formazan crystals (2–3 h at 37°C 
with 10%SDS/10mM HCl), absorbance was measured at 
570nm in a VersaMax Elisa Microplate Reader (Molecular 
Devices). Cell viability was determined counting cells 
after Trypan blue labeling. Control and Doxy-treated cells 
(2 μg/ml, 72 h) were detached, mixed with a 0.4% Trypan 
blue/PBS solution (1:1), loaded on a hemocytometer and 
counted.
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Anchorage-independent growth
Cells were resuspended in warmed solution of 0.3% 
agarose in complete medium -/+2 μg/ml Doxy and seeded 
at 105cells/60mm dishes with a bottom layer of 0.5% 
agarose. Cells were re-fed every 3 days with complete 
medium (300μl/dish, -/+Doxy). Plates were stained with 
0.5 ml of 0.005% crystal violet/water for 1 h. Colonies 
with diameter ≥ 0.1mm were counted after 20 days. Three 
independent experiments were performed in triplicate.
Immunoblotting
Cell lysed from three subconfluent plates were 
analyzed by immunoblotting as previously described [36].
RNA preparation, qRT-PCR of mRNA
Cell cultures of MDA-MB-231-Tet-On-shRNA-c-Src 
were incubated -/+ Doxy (2 μg/ml) for 72 h. RNA was 
isolated from three independent experiments performed 
in triplicate using RNeasy kit (Qiagen). After testing 
for RNA integrity, triplicate RNAs from each treatment/
experiment were pooled. c-Src mRNA expression was 
determined by using TaqMan probe for human c-Src 
(Hs01082246_m1), TBP (TATA-box Binding Protein) 
was used as endogenous control (Life Technologies). For 
CCN1 (Cyr61) qRT-PCR was performed using SYBR 
Green Master Mix (Life Technologies). Specific primers 
for Cyr61 and GAPDH, used as endogenous control, 
were previously described [88]. Gene expression was 
calculated as difference in cycle threshold (∆Ct) between 
target gene and GAPDH and TBP respectively; ∆∆Ct 
was the difference between ∆Ct values of test sample and 
that of control. Relative expression of target genes was 
calculated as 2-∆∆Ct.
Cell migration
MDA-MB-231-Tet-On-shRNA-c-Src cells were 
seeded in complete medium (3.5x105cells/well in 
6-well plate) and grown to confluence (48 h, -/+2 μg/ml 
Doxy). SUM159PT cells were seeded in complete 
medium (2.25x105cells/well in 6-well plate) and grown 
to confluence 24 h. The monolayer was scratched with 
a 200μl micropipette tip and washed with fresh medium 
to remove floating cells. Complete medium was added 
-/+ Doxy to MDA-MB-231-Tet-On-shRNA-c-Src. To test 
for the biological role of secreted Cyr61 in migration, 
cultures of MDA-MB-231-Tet-On-shRNA-c-Src in 
absence of Doxy were treated with 4 μg/ml of anti-Cyr61 
(Cyr61) or with the corresponding amount of normal 
rabbit serum (Ctrl) for 48 h. For SUM159PT complete 
medium -/+1 μg/ml neutralizing antibody Cyr61 was 
added to cultures. Photomicrographs were taken at 0 and 
20 h with a Microscope Cell Observer Z1 system (Carl 
Zeiss AG) equipped with controlled environment chamber 
and Camera Cascade 1k. Migration was quantified using 
wound-healing tool of ImageJ.
Transendothelial migration
Transendothelial migration of MDA-MB-231-
Tet-On-shRNA-c-Src was performed growing HUVEC 
cells over gelatin-coated cell culture inserts for 
24-well plate (8 μm-pore PET membranes, Falcon). After 
48 h -/+Doxy, 5x104cells were seeded over HUVEC 
monolayer. The lower chamber was filled with 600μl of 
20% FBS-supplemented medium. In parallel, a control 
was performed in the same conditions by seeding HUVEC 
cells alone, in order to test their spontaneous migration. 
After 22 h, transmigrated cells were detached and 
counted in hemocytometer. The number of Doxy-treated 
transmigrated cells was expressed as percentage respect 
to control transmigrated cells (100%).
Invasion assay
MDA-MB-231-Tet-On-shRNA-c-Src cells were 
seeded on the upper chamber (5x104/well/200μl) in serum-
free medium -/+2 μg/ml Doxy. The lower chamber was 
filled with 600μl of 20% FBS-supplemented medium 
-/+ Doxy; 22 h later, after removing cells on top of inserts, 
those on lower surface fixed and stained as previously 
described [31].
Secretome fractionation
Conditioned media from cell cultures were used 
to prepare soluble and exosomal fractions of secretome 
by differential centrifugation, as described [52]. The 
soluble secretome, supernatant of 100, 000xg, 70min, 
was concentrated by methanol/chloroform precipitation. 
Microvesicle pellet was resuspended in RIPA buffer for 
immunoblotting analyses.
Transient transfection of siRNA for Cyr61and 
Rab27a
MDA-MB-231 cells (105cells/well, 6-well plate) 
were seeded in complete medium without antibiotics. 
Next day, cells were transfected using Dharmafect 4 with 
20nM of siRNA-Cyr61 or 50nM of esiRNA-Rab27a. For 
control, 20/50nM scramble siRNA (Life Technologies) 
were used. After 8 h medium was changed. For siRNA-
Cyr61 transfection, cells were detached 40 h later 
and used for invasion, transendothelial migration or 
immunoblotting (72 h) assays. When esiRNA-Rab27a 
was employed, media culture was changed after 72 h 
and cells were then maintained 24 h in serum-free 
media. Secretome and total cell extracts were used for 
immunoblotting analyses.
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Secretome protein digestion, iTRAQ-4-plex® 
labeling and RP-LC-MALDI ToF/ToF MS 
analysis
Cultures of MDA-MB-231-shRNA-c-Src were 
grown for 48 h in complete media -/+ Doxy (2 μg/ml). 
Cultures were then washed with phenol red and serum 
free DMEM and incubated for additional 24 h in this 
medium -/+ Doxy (2 μg/ml). Total secretome, fraction S3 
(diagram Figure 4A) was collected. For digestion, 20 μg 
of protein from each secretoma condition (-/+ Doxy) 
was precipitated with methanol/chloroform. Proteins 
from each condition (20 μg) were reduced with TCEP 
[Tris(2-carboxyethyl)phosphine], alkylated with MMTS 
(methyl methanethiosulfonate), digested with trypsin 
and labeled with iTRAQ reagent. Labeling tags 116 and 
117 were used for controls and 114 and 115 for Doxy-
treated replicates. Each digested, labeled and pooled 
samples were desalted using Sep-Pak C18 Cartridges 
(Waters), vacuum concentrated and reconstituted with 
0.1% heptafluorobutyric acid (HFBA). An aliquot 
was injected with a TEMPO nanoMDLC HPLC (AB 
SCIEX) and eluted onto an Onyx monolith C18 column 
(150 mm x 0.1 mm) (Phenomenex). α-cyano-4-hidro-
cinnamic acid MALDI matrix diluted in 70% acetonitrile 
and 0.1%TFA aqueous solution, were mixed post-column 
with eluted peptides. Spots were deposited on MALDI-
plate (Opti-TOF™ LC MALDI Insert, AB SCIEX). 
A MALDI TOF/TOF 4800 (AB SCIEX) mass 
spectrometer was used for acquisition and processing 
of data. MS data from spots was acquired in positive 
reflector ion mode in mass range of 800–3500m/z by 
accumulation of 1200 laser shots. MS/MS spectra were 
generated by 2kV collisions with air. Maximal 2000 laser 
shots were accumulated for MS/MS spectra. Protein 
identification and quantitation on each of the two data sets 
were done by using MASCOT-v2.3.01 (Matrix Science) 
and Phenyx-v2.6 (GeneBio) search engines. Searches 
were performed against UniProtKB/Swiss-Prot human 
database to estimate false positive rate (FDR) below 0.5%, 
which boosted reliability of data. Differential expression 
of proteins between controls and Doxy-treated samples 
was determined by calculating weighted average ratios 
of peptides for each identified protein. Only proteins 
having at least two quantitated peptides detected by both 
Mascot and Phenyx in control and + Doxy conditions were 
considered in quantitation.
Statistical analyses
Mean values, standard deviation and statistical 
significance between data from two different experimental 
conditions were determined by two-tail Student t-test. 
For co-localization analyses by confocal microscopy, 
Pearson’s coefficient (Bolte and Cordelieres, 2006) [56] 
was employed. ANOVA followed by Tukey post-hoc test 
were used for comparative analyses of Cyr61 expression 
among subtypes of breast cancer cell lines.
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